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Background: The dismal outcome of malignant peripheral nerve sheath tumor (MPNST) highlights the necessity of
finding new therapeutic methods to benefit patients with this aggressive sarcoma. Our purpose was to investigate
epidermal growth factor receptor (EGFR) as a potential therapeutic target in MPNSTs.
Patients and methods: We performed a microarray based-comparative genomic hybridization (aCGH) profiling of
two cohorts of primary MPNST tissue samples including 25 patients treated at The University of Texas MD Anderson
Cancer Center (MD Anderson) and 26 patients from Tianjin Medical University Cancer Institute & Hospital (TMUCIH).
Fluorescence in situ hybridization (FISH) method was used to validate the gene amplification detected by aCGH
analysis. Another independent cohort of 56 formalin fixed paraffin embedded (FFPE) MPNST samples was obtained
to explore EGFR protein expression by immunohistochemical analysis. Cell biology detection and validation were
performed on human MPNST cell lines ST88-14 and STS26T.
Results: aCGH and pathway analysis of the 51 MPNSTs identified significant gene amplification events in EGFR
pathway, including frequent amplifications of EGFR gene itself, which was subsequently validated by FISH assay.
High expression of EGFR protein was associated with poor disease-free and overall survival of human MPNST
patients. In human MPNST cell lines ST88-14 and STS26T, inhibition of EGFR by siRNA or Gefitinib led to decreased
cell proliferation, migration, and invasion accompanied by attenuation of PI3K/AKT and MAPK pathways.
Conclusion: These results suggest that EGFR is a potential therapeutic target for MPNST.
Keywords: Malignant peripheral nerve sheath tumor, Epithelial growth factor receptor, Targeted therapy,
Microarray-based comparative genomic hybridization, Gene amplification, GefitinibBackground
Malignant peripheral nerve sheath tumors (MPNSTs) are
highly malignant sarcomas derived from the neural crest
[1,2]. The relative rarity of MPNST and the lack of any
specific diagnostic, radiologic, or pathologic signature pose
considerable management challenges for the disease. Even
with multidisciplinary treatment, the prognosis for patients
with MPNST is still very poor [1,2]. The dismal outcome* Correspondence: yangjilong@tjmuch.com; zhuze_2006@126.com
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stated.highlights the necessity of finding new therapeutic methods
to benefit patients with this aggressive sarcoma [1-3].
Recent microarray-based comparative genomic hybridi-
zation (aCGH) studies in MPNST detected some genetic
aberrations associated with prognosis and implicated in
the pathogenesis and development of the disease, such
as alteration of topoisomerase (DNA) II alpha (TOP2A),
cyclin-dependent kinase 4 (CDK4), and forkhead box M1
(FOXM1) and frequent gains of epidermal growth factor
receptor (EGFR), insulin-like growth factor 1 receptor
(IGF1R), cyclin-dependent kinase 6 (CDK6), potassium
channel, subfamily K member 12 (KCNK12), met proto-
oncogene (MET), and platelet-derived growth factor
receptor alpha polypeptide (PDGFRA) [3-7]. These are
important findings with clinical relevance, because EGFRThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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several types of cancers, such as Gefitinib and Erlotinib in
lung cancer [8]. EGFR has been implicated in promoting
peripheral nerve tumor formation and malignant trans-
formation in neurofibromatosis type I (NF-1)–associated
MPNST [2]. Furthermore, tumor-sphere formation requires
signaling from EGFR tyrosine kinase, also exemplifying the
importance of EGFR in neurogenic tumor transformation
[9]. In a mouse model reminiscent of neurofibroma, EGFR
blockade consistently prevented peripheral nerve disruption
[10]. Along with these findings, the finding by Keizman
and colleagues that EGFR expression has prognostic value
in both NF-1–associated and sporadic MPNST suggests
that EGFR-targeted therapy may be a potential treatment
for MPNST [11].
With the working hypothesis that EGFR expression is a
key targetable oncogenic event in MPNST, we performed
aCGH profiling on 51 primary MPNST tissues. In addition,
EGFR amplification status was specifically probed by fluor-
escence in situ hybridization (FISH) in 26 samples out of
the 51 tissues. Another independent cohort of 56 formalin
fixed paraffin embedded (FFPE) MPNST samples was
obtained to explore EGFR protein expression by immuno-
histochemical analysis. We examined the effects of EGFR
inhibition on cell proliferation and EGFR-associated down-
stream pathways in two human MPNST cell lines, STS26T
and ST88-14. The findings from our integrated genomic
and molecular studies suggest that EGFR is a potential key
therapeutic target for patients with MPNST.
Results
MPNST in diverse populations exhibited similar recurrent
genetic aberrations that significantly altered multiple
signaling pathways
We first compared the genomic aberrations of the two
cohorts from Tianjin Medical University Cancer Institute &
Hospital (TMUCIH) and The University of Texas MD
Anderson Cancer Center (MD Anderson) (Figure 1A
and B). The most significant difference is the higher over-
all aberration rate in the American patients, although the
overall pattern of aberrations remains similar. The cause
of the difference is unknown, possibly related to ethnicity
and the minor differences in aCGH measurements between
the institutions.
We also investigated the translational relevance of these
genes by correlating the loci with several clinical parameters
such as tumor location, clinical AJCC (American Joint
Committee on Cancer) stage of tumor, tumor size, local
recurrence, metastasis, and survival between the two
cohorts. As reported in previous paper [3], we could not
associate any individual aberration with patient survival,
suggesting that multiple events might co-occur to affect
survival. However, correlating the overall frequency of
CNAs with survival did not implicate increased genomicinstability in inducing statistically significant survival
effects [3].
Given the minor difference in global aberration rates,
we maintain that the cohorts were comparable and can
be combined for the pathway analyses. Combining the
cohorts from different institutions is critical because
acquisition of MPNST samples is technically difficult.
Integration of copy number profiles of the 51 individual
samples yielded 4901 frequent deletions and 2599 amplifi-
cations in the primary MPNST tissue samples [3]. The
most frequent deletion was 9p21.3 (harboring tumor
suppressors cyclin-dependent kinase inhibitor 2A and 2B),
with approximately 65% of patients affected. To investigate
the potential effects of these alterations at the signaling
pathway level, we computed pathway enrichment scores for
each pathway by a method as reported previously [3,12].
This analysis identified 11 pathways that were statistically
significantly altered in MPNST, including TFF, ERK, ARF,
IGF1R, and EGFR signaling pathways. Taking into account
previous reports that IGF1R pathway is a potential
therapeutic target for MPNST patients, and the cross-talk
between IGF1R and EGFR signaling pathways was detected
in other types of cancers [3,13-17], the great success of
EGFR-targeted therapy in lung cancer prompted us to put
emphasis on the EGFR pathway in this analysis, with the
hypothesis that the EGFR signaling pathway is a potential
therapeutic target and that blocking both IGF1R and EGFR
simultaneously in MPNST might result in a synergistic
antitumor effect.
Extensive EGFR pathway alterations and high expression
of EGFR protein correlated with shorter patient survival
EGFR, amplified in 37% (19/51) of our samples, has been
suggested as a potential target in MPNST [18-20]. The
comparison of the two cohorts indicated that the frequency
of EGFR amplification did not differ significantly between
TMUCIH samples (35%) and MD Anderson samples
(40%). In addition to EGFR, we investigated the frequency
(Figure 1C) and pattern (Figure 1D) of gene alterations in
the EGFR signaling pathway genes. At least one EGFR
pathway gene was altered in 84% of the samples. Some
of the most significantly aberrated genes included growth
factor receptor-bound protein 2 (GRB2) (amplified in 31%),
Harvey rat sarcoma viral oncogene homolog (HRAS) (de-
leted in 35%), and mitogen-activated protein kinase 1
(MAPK1) (deleted in 41%) in ERK signaling branch, v-akt
murine thymoma viral oncogene homolog 1 (AKT1) (deleted
in 31%) in AKT signaling branch, and Janus kinase 2 (JAK2)
(deleted in 47%) in JAK-STAT signaling branch (Figure 1C).
Interestingly, we found that there were a few co-aberrated
genes in EGFR signaling pathway such as signal transducer
and activator of transcription 1 (STAT1), cAMP responsive
element binding protein 1 (CREB1), epidermal growth factor
(EGF), nuclear factor of kappa light polypeptide gene
Figure 1 (See legend on next page.)
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Figure 1 Copy number alterations in 26 MPNST samples from Tianjin Medical University Cancer Institute & Hospital (TMUCIH) and 25
MPNST samples from MD Anderson Cancer Center and genetic amplifications of the EGFR signaling pathway, including those of the
EGFR gene itself. (A,B) Recurrent gene copy alteration patterns in 26 MPNST from TMUCIH patients (A) and 25 MPNST from MD Anderson
Cancer Center patients (B). The x-axis numbered with 1–22 denotes chromosome numbers. The y-axis shows recurrence of gains (positive axis)
and losses (negative axis) for each measured locus evenly distributed in chromosomal order. Recurrence rates that exceed the threshold (dashed
line) are color-coded to emphasize the locations of significantly recurrent aberrations. Red denotes significantly recurrent amplifications and green
denotes significantly recurrent deletions. Gray represents nonsignificant recurrence of aberrations. (C) Aberration rates of EGFR signaling pathway
genes in all 51 MPNST samples. The number on the left side is the deletion frequency (Del) of the gene, and the number on the right side is the
amplification rate (Amp). Color-coding indicates the type and frequency of aberration (red amplified, green deleted). (D) Hierarchical clustering of
aberrations of EGFR signaling pathway genes in all 51 MPNST samples showed a panoramic view of genetic aberrations in EGFR signal pathway.
Red means amplification and green means deletion.
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alpha (GSK3A) and v-akt murine thymoma viral oncogene
homolog 2 (AKT2) (Figure 1C and D). Kaplan-Meier sur-
vival analysis showed that none of the gene copy number
alterations had a significant effect on disease-free survival
or overall survival. The lack of effect may be due to the
small sample size and short follow-up period.
We found that the pattern of EGFR amplification was
in large fragments and the amplification was accompanied
by 7p amplifications (Figure 2A). These observations were
consistent with the literature in that EGFR and other
growth factor–related oncogenes are activated by gene
amplifications [21-23]. To validate the pattern of genetic
amplifications of EGFR, FISH assays with LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen Probe kit were
performed in the 26 MPNST samples from TMUCIH
(the matching fresh-frozen MPNST tissues were used in
the aCGH analysis ) (Figure 2B), which confirmed EGFR
gene amplification in large fragment pattern in tumor
cells (Figure 2C). Among nine MPNST samples in which
aCGH analysis showed EGFR amplification, seven had
multiple EGFR gene signals detected by FISH assay.
These two methods showed consistent results (t = 18.09,
P = 5.47E-5; Spearman correlation = 0.834).
Though Kaplan-Meier survival analysis showed that the
gene copy number alterations of EGFR detected by either
aCGH or FISH had no significant effect on disease-free or
overall survival, the FISH assay validated and confirmed
the EGFR amplification and its pattern.
To further understand the clinical significance of EGFR
expression in MPNST, we analyzed EGFR protein expres-
sion in the independent set of 56 FFPE MPNST tissue
samples from TMUCIH by immunohistochemistry.
The EGFR protein expression showed various patterns,
from negative and weak positive to moderate and strong
positive, accounting for 41.1% (23/56), 39.3% (22/56), 7.1%
(4/56), and 12.5% (7/56) of cases, respectively (Figure 2D).
The EGFR protein expression correlated positively with
the EGFR gene amplification detected by FISH assay,
suggesting that genetic alteration of EGFR plays an
important role in the elevated EGFR protein expres-
sion (Fisher exact test =10.85, P = 0.004, Spearmancorrelation = 0.47). Kaplan-Meier survival analyses showed
that patients whose tumor expressed a high level of EGFR
protein (moderate and strong positives, 19.6% [11/56])
had significantly shorter disease-free and overall survival
than patients whose tumor expressed a low level of EGFR
protein (negatives and weak positives, 80.4% [45/56];
Figure 2E and F).
Inhibition of EGFR in STS26T and ST88-14 decreased tumor
cell proliferation, invasion, and migration by blockading
activation of AKT and PI3K pathway signaling
The next step in our investigation of EGFR as potential
therapeutic target in MPNST was to evaluate the effect
of EGFR inhibition in human MPNST cell lines STS26T
and ST88-14. In the in vitro STS26T cell culture system,
EGFR siRNA significantly decreased expression of EGFR
and its phosphorylated form (Figure 3A). At the same time,
this inhibition of EGFR expression significantly decreased
the expression of the activated forms of AKT and PI3K
signal pathway components pPI3K, pAKTS473, pERK, and
pBad (Figure 3A). Functional experiments showed that
inhibition of EGFR significantly reduced cell proliferation
(Figure 3B), invasion (Figure 3C and D), and migration
(Figure 3E and F) in contrast to the control siRNA.
Similarly, in ST88-14 cells, the EGFR siRNA significantly
decreased the expression of EGFR, phosphorylated EGFR,
and the activated forms of AKT and PI3K signal pathway
components, as well as tumor cell proliferation, invasion,
and migration (Figure 4A-F).
To investigate the therapeutic role of EGFR in MPNST,
STS26T and ST88-14 cells were treated with EGFR tyro-
sine kinase inhibitor Gefitinib. Gefitinib (ZD1839) is often
referred to as a “specific” or “selective” inhibitor of EGFR
and the maximum plasma concentrations resulting from
clinically relevant doses are 0.5-1 μM or more, well within
the IC50 values of several tyrosine kinases [24]. However,
the selectivity of Gefitinib for inhibition of EGF-driven cell
growth was demonstrated by the large difference in IC50
in the presence or absence of EGF, such as cytotoxicity
was not observed at Gefitinib concentrations up to 25 μM
[24]. To get the effective concentration in MPNST cell line,
IC50 data were interpolated by nonlinear regression
Figure 2 Genetic amplification and increased expression of EGFR protein in TMUCIH MPNST samples and its clinical significance.
(A) Large-fragment amplification of chromosome 7p, including the EGFR gene. Arrow shows the location of the EGFR gene, which is amplified in
37% of the cases. (B) The EGFR/CEP7 FISH probe. (C) FISH analysis detected amplification of the EGFR gene in a representative tumor sample.
Green signal represents the centromere and orange signal represents the EGFR gene. (D) EGFR protein expression in representative human
MPNST tissue. (E,F) Patients whose MPNST expressed a high level of EGFR had shorter disease-free survival (E) and shorter overall survival (F).
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software (version 3.78; Microcal Software Inc., Northampton,
MA). At a median inhibitory concentration (IC50) of 10
μM, Gefitinib significantly inhibited STS26T cell prolifera-
tion in the presence of EGF (10 ng/ml) (Figure 5A-C).
Furthermore, Gefitinib inhibited the activation of EGFR
by decreasing expression of pEGFRY1068 (Figure 5C),
along with decreases of pPI3K, pAKTS473, pERK, and
pBad (Figure 5D). In ST-8814 cells, Gefitinib treatment
had similar effects [3].
Inhibition of EGFR did not induce activation of IGF1R
signaling pathway
Inspired by the reported cross-talk between the IGF1R
and EGFR signaling pathways [13-17], we blocked bothEGFR and IGF1R in MPNSTcells to evaluate the possibility
of synergistic or antagonistic effects. Because no IGF1R
protein expression was detected in STS26T, while ST88-14
cells expressed both IGF1R and EGFR, we chose ST88-14
cells to explore the effect of inhibiting EGFR and IGF1R in-
dividually and in combination. In ST88-14 cells, inhibition
of EGFR with siRNA or Gefitinib did not induce activation
of the IGF1R signal pathway. Furthermore, inhibition of
EGFR and IGF1R with siRNA or Gefitinib/MK-0646 did
not induce any synergistic effects [3].
Discussion
MPNST occurs either sporadically or in association with
NF-1, and in 2002 the World Health Organization coined
the term “malignant peripheral nerve sheath tumor” to
Figure 3 Down-regulation of EGFR by EGFR siRNA in STS26T MPNST cells significantly decreased tumor cell proliferation, invasion, and
migration by blocking the PI3K/AKT and MAPK pathways. (A) EGFR siRNA decreased EGFR expression and activation. Activated forms of
PI3K/AKT and MAPK pathway factors decreased with EGFR inhibition. (B) EGFR siRNA significantly decreased tumor cell proliferation compared
with the nonspecific control siRNA. (C, D) EGFR siRNA significantly decreased tumor cell invasion compared with the nonspecific control siRNA:
cell invasion (C) and cell counts (D). (E, F) EGFR siRNA significantly decreased tumor cell migration compared with the nonspecific control siRNA:
cell migration (E) and cell counts (F). * indicate P-values <0.05.
Du et al. Journal of Hematology & Oncology 2013, 6:93 Page 6 of 12
http://www.jhoonline.org/content/6/1/93replace previous heterogeneous and often confusing
terminologies [25]. It is a highly malignant sarcoma for
which more effective therapeutic strategies are urgentlyneeded [26]. In this study, we carried out genomic and
molecular studies of MPNST, both human tumors and cell
lines, to identify potential therapeutic targets. Our findings
Figure 4 Down-regulation of EGFR by EGFR siRNA in ST88-14 MPNST cells significantly decreased tumor cell proliferation, invasion,
and migration by blocking PI3K/AKT and MAPK pathways. (A) EGFR siRNA decreased EGFR expression and activation. Activated forms of
PI3K/AKT and MAPK pathway factors decreased with EGFR inhibition. (B) EGFR siRNA significantly decreased tumor cell proliferation compared
with the nonspecific control siRNA. (C, D) EGFR siRNA significantly decreased tumor cell invasion compared with nonspecific control siRNA: cell
invasion (C) and cell counts (D). (E, F) EGFR siRNA significantly decreased tumor cell migration compared with nonspecific control siRNA: cell
migration (E) and cell counts (F). * indicate P-values <0.05.
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Figure 5 EGFR kinase inhibitor gefitinib decreased STS26T MPNST tumor cell proliferation by blocking the PI3K/AKT and MAPK
pathways. (A) The IC50 of gefitinib in tumor cells was about 10 μM. (B) At a 10-μM concentration, gefitinib significantly decreased tumor cell
proliferation compared with the MOCK and DMSO controls. (C) Gefitinib significantly decreased activation of EGFR. (D) Gefitinib significantly
decreased activation of the PI3K/AKT and MAPK signaling pathways. * indicate P-values <0.05.
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EGFR signaling pathway in these tumors, but also indicate
that genomic amplification and high expression of EGFR
are key targetable oncogenic events in MPNST patients.
Among a number of studies that implicated EGFR as
an important molecule in MPNSTs, the most important
contribution of our investigation is the exhaustive demon-
stration of the genetic evidence that the EGFR signaling
pathway can serve as a potential therapeutic target in
MPNST. EGFR expression in neurogenic tumors has been
reported by several investigators, and the data showed that
it is a very important receptor in neurofibromatosis 1,
neurofibroma, and MPNST [11,19,27,28]. The improving
understanding of the role of EGFR in the pathogenesis of
MPNST, the limitations of available treatments for MPNST,
and the successful use of EGFR-targeted therapy in
non-small cell lung cancer make a strong case for EGFR
as a potential therapeutic target in MPNST [11,19,27,28].
Huang and colleagues reported that the MPNST cell lines
from the NF-1:p53 mouse model can be blocked by an
antagonist of EGFR or inhibition of its downstream target
PI3K [29]. Holtkamp and colleagues observed dose-
dependent inhibition of MPNST cell proliferation me-
diated by erlotinib, an EGFR-targeted tyrosine kinase
inhibitor [19]. By now, nine of the approximately 55
finished or ongoing clinical trials in MPNST are phaseI-III clinical trials involving a tyrosine kinase inhibitors
such as imatinib, erlotinib, PLX3397, dasatinib, suniti-
nib, and sorafinib (http://clinicaltrials.gov/ct2/results?
term=MPNST&Search=Search) [30-33]. In the present
study, integrated genetic and molecular profiles confirmed
genetic alterations of EGFR signaling pathway, including
amplification of EGFR gene itself and the high protein
expression of EGFR, are key targetable oncogenic events
in MPNSTs. Our solid genetic data including aCGH,
pathway analysis, and FISH validation provided genetic
evidence of this target therapy.
The reported rates of EGFR protein expression in
MPNST vary from 43% to 86% [2,11,27,28]. This variation
in expression pattern might have been due to several
factors; the most important one might be the gene dosage
of EGFR. In the study by Holtkamp et al., FISH analysis
revealed increased EGFR dosage in 28% of MPNST,
and level of EGFR protein expression was significantly
associated with increased EGFR gene dosage [19]. In the
present study, the level of EGFR protein expression was
also correlated to EGFR gene amplification as evaluated
by FISH and immunohistochemical assays, indicating
that EGFR dosage plays an important role in aberrant
EGFR protein expression. However, Tabone-Eglinger et al.
detected EGFR expression in 86% of MPNST and no amp-
lification of the EGFR locus, and the EGFR expression was
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ated with high-grade and p53-positive areas [28,34]. There-
fore, other factors might be involved in EGFR expression,
such as NF-1, p53 mutation, and MDM2 expression
[27,28,34]. EGFR gene mutation also may be one of the
factors, in MPNST a portion of EGFR expression appears
as EGFR VIII and is linked to exon 17–21 deletion [27].
Somatic mutations of the EGFR gene were more sensitive
to Gefitinib, being completely inhibited at 0.2 μmol/L,
whereas wild-type EGFR required 2 μmol/L gefitinib
for complete inhibition [35]. In this sense, EGFR expres-
sion and/or mutational status, which had been frequently
observed, might be proposed as signatures to identify
MPNST patient subtypes that might be more sensitive
to EGFR targeted therapy.
Inhibition of EGFR in colon carcinoma cells promotes
activation of the IGF1R signaling pathway, and inhibition
of EGFR-directed MAPK shifts regulation of Akt from
EGFR toward IGF1R [15]. Furthermore, acquired resistance
to EGFR tyrosine kinase inhibitors in cancer cells is
mediated by loss of IGF-binding proteins, as was shown in
A431 squamous cancer cells [36]. In rhabdomyosarcoma
cell line Rh36, which is resistant to BMS-536924 (a small
molecule inhibitor of IGF1R), combined analysis of targeting
EGFR and IGFIR pathways revealed enhanced inhibitory
activities [29]. However, in neither the present study
nor our previous study was any additive antitumor effect
observed with combined inhibition of IGF1R and EGFR,
suggesting a lack of cross-talk between IGF1R and EGFR
pathways in MPNST [3]. Thus, any insight and conclusion
drawn from these cell line results would need more
circumspect investigations considering several issues
such as tumor types, culture conditions, and the host
environment. Therefore, our investigation of EGFR/IGF1R-
targeted therapy highlighted the urgent need to clarify the
possible crosstalk mechanisms in MPNST.
In summary, integrated genetic and molecular profiles
confirm genetic alterations of the EGFR signaling pathway,
including amplification of the EGFR gene itself and the high
expression of EGFR protein, as potential key targetable
oncogenic events in MPNST. Inhibition of EGFR in vitro
induced inhibition of MPNST tumor cell proliferation,
invasion, and migration via inhibition of the PI3K/AKT
and MAPK pathways. Though need more investigation
and clinical trials to confirm, these findings suggested that
inhibition of EGFR might be a valid therapeutic choice,
supplementing routine treatments such as surgery and
radiotherapy for MPNST patients.
Materials and methods
Patients and primary tumors
Fifty-one archived MPNST samples and matching patient
records were acquired from The University of Texas MD
Anderson Cancer Center (MD Anderson; 25 FFPE tumorsamples) and Tianjin Medical University Cancer Institute &
Hospital (TMUCIH; 26 fresh-frozen tumor samples with
matched FFPE tissues) [3]. All samples were evaluated by
two pathologists (one from each institution) to confirm the
diagnosis and ensure that each specimen contained at least
90% of tumor. TMUCIH cohort was also used for FISH
validation. An independent cohort of 56 FFPE tumor
samples was acquired from TMUCIH for immunohis-
tochemical validations only.
Patient information collected included age, sex, tumor
location, largest diameter of the tumor, clinical AJCC
(American Joint Committee on Cancer) stage of the
tumor, time to recurrence, metastatic status, treatments,
and outcome [3]. The presence of the NF-1 syndrome was
determined by the NIH criteria [37]. Tissue and infor-
mation collection for this retrospective study were
approved by the Institutional Review Boards (IRBs) at
Tianjin Medical University Cancer Institute & Hospital
(TMUCIH) and The University of Texas, MD Anderson
Cancer Center and with patients’ consent.
Array CGH hybridization and bioinformatic analysis
The genome-wide copy number levels were mapped
by aCGH for the 51 primary tumor samples using com-
mercially available normal genomic DNAs as reference
(Clontech Laboratories, Inc., Mountain View, CA) [3]. The
tumor genomic DNAs were isolated according to standard
procedures and the labeled genomic DNAs were hybridized
by using the Agilent 4 × 44 k Human Genome CGH
Microarray kit (Agilent Technologies, Santa Clara, CA).
The aCGH data analysis was conducted as described
previously [3,12].
FISH analysis
The Vysis LSI EGFR SpectrumOrange/CEP 7 Spectrum-
Green Probe kit was used for the FISH detection of EGFR
(Abbott Laboratories, Abbott Park, IL). The CEP 7 probe
showing green signal indicates the chromosome 7 centro-
mere, and the EGFR probe shows orange signal representing
the EGFR gene copy number.
Twenty-six FFPE tissues of 51 samples from TMUCIH
were subjected to FISH (matching fresh-frozen MPNST tis-
sues were used in the aCGH analysis) as described in our
previously published paper [12]. Staining of experimental
slides was accompanied by concurrent staining of positive
and negative control slides to monitor assay performance
and to assess the accuracy of signal enumeration.
Alterations of EGFR gene copy number were evaluated
according to the established methods by two pathologists
in a blinded fashion [12,38,39]. In the informative cases
(>90% of nuclei showed hybridization signals), the presence
of more than two orange and green signals in each tumor
cell with a ratio of orange signals to green signals
greater than 1 was considered focal EGFR amplification.
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in each tumor cell with a ratio equal to 1 was considered
large-fragment amplification. The presence of only two
orange and green signals in each tumor cell or a ratio less
than 1 was considered no EGFR amplification.
Immunohistochemical analysis
EGFR protein expression was detected in anther inde-
pendent TMUCIH cohort of 56 FFPE tissues by immuno-
histochemical methods using the EGFR antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) in 1:100 dilutions as
described previously [3,16,17]. Nonimmune rabbit serum
at the same concentration was used as negative control.
The expression levels of EGFR were estimated according to
criteria previously reported [17,40]. Scoring was performed
according to the percentage of positive cells: <5% was
classified as negative, 6-30% was classified as a weak
positive, 31-60% as a moderate positive, and >60% as a
strong positive. In the survival analysis, the negative and
weak positives were considered low EGFR expression, the
moderate and strong positives as high EGFR expression.
Cell culture and reagents
MPNSTcell lines ST88-14 and STS26T were authenticated
by short tandem repeat DNA fingerprinting. The ST-8814
line is NF-1−/− and STS26T is NF-1+/+. The cell lines were
maintained in Eagle’s minimum essential medium and
incubated at 37°C in a humidified atmosphere containing
7.5% CO2. Gefitinib was stored at −20°C as a 20 mM
concentration solution in dimethyl sulfoxide (DMSO).
MK-0646, a monoclonal antibody against insulin growth
factor-1 receptor (IGF1R), was dissolved in sterile water at
a concentration of 20 mg/mL and stored at −20°C.
Small-interfering RNA transfections
For the siRNA studies, an EGFR siRNA (sc-29301, Santa
Cruz Biotechnology) previously proven specific and effect-
ive was used to block EGFR expression in MPNST cells
according to the manufacturer's instructions. Because of
the cross-talk of the IGF1R and EGFR pathways [13-15],
a smart pool of three double-stranded siRNAs against
IGF1R (IGF1R-NM-000875) was used as previously re-
ported [3,17,40]. In all siRNA transfection experiments,
nonspecific siRNA (D-001206-01-05) purchased from
Dharmacon (Lafayette, CO) was used as a control.
Western blot analysis and cell proliferation, invasion,
and migration assays
Western blot analysis of treated MPNST cells was per-
formed as previously described [3]. Antibodies to EGFR,
AKT, PI3K, IRS-1 ERK, and their phosphorylated forms
were obtained from Abcam (Cambridge, MA), Sigma
Chemical (St. Louis, MO), Santa Cruz Biotechnology, and
Cell Signaling Technology (Beverly, MA). Cell proliferationwas analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay, and cell invasion and migra-
tion were analyzed by Transwell migration assays (EMD
Biosciences, San Diego, CA) according to procedures
reported previously [3].
Statistical analyses
The statistical analyses were performed as described previ-
ously [3,12]. The SPSS software (version 16.0; SPSS, Inc.,
Chicago, Ill) and Matlab (R2012b 64-bit, MathWorks Inc,
Natick, MA) were used in the analyses. The clinical and
pathologic features of the 25 MD Anderson and 26 TMU-
CIH MPNST cases were compared via the chi-square test,
an analysis of variance, the Student’s t-test, or the Fisher’s
exact test, as appropriate. The relationships between
survival rates and EGFR gene amplification or EGFR
protein expression were evaluated by comparing the
differences of Kaplan-Meier survival estimators by Mantel-
Cox test. Associations between copy number alterations
and clinical variables were computed by using the Fisher’s
exact test. Pathway enrichment analysis was performed on
the genes that were either amplified or deleted in at
least 20% of the samples by a standard hypergeometric
test. Enrichment P-values were computed for all signaling
pathways included in Biocarta (http://www.biocarta.com/).
A P-value less than 0.05 was considered as the threshold
of statistical significance in all tests.
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